The great escape: tumour cell plasticity in resistance to targeted therapy

Gain Fat—Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis

(2019) Dana Ishay-Ronen et al.   CANCER CELL

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation

(2019) Jason E. Long et al.   CELL DEATH AND DIFFERENTIATION

Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy

(2018) Guan-Jun Yang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery

(2018) Shanshan Gu et al.   BIOESSAYS

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

(2018) Jennifer Tsoi et al.   CANCER CELL

Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma

(2018) Markus Eberl et al.   CANCER CELL

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

(2018) Liqin Wang et al.   CELL

Small molecule KDM4s inhibitors as anti-cancer agents

(2018) Hongzhi Lin et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

(2018) Antoine Italiano et al.   LANCET ONCOLOGY

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment

(2018) Hetal Patel et al.   MOLECULAR CANCER THERAPEUTICS

Taming the Notch Transcriptional Regulator for Cancer Therapy

(2018) Luca Tamagnone et al.   MOLECULES

Noncanonical hedgehog pathway activation through SRF–MKL1 promotes drug resistance in basal cell carcinomas

(2018) Ramon J Whitson et al.   NATURE MEDICINE

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

(2018) Julia Boshuizen et al.   NATURE MEDICINE

Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling

(2018) Pernilla Roswall et al.   NATURE MEDICINE

Cellular plasticity and the neuroendocrine phenotype in prostate cancer

(2018) Alastair H. Davies et al.   Nature Reviews Urology

The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML

(2018) Daniel Gerlach et al.   ONCOGENE

ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?

(2018) Charbel Hobeika et al.   Personalized Medicine

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

(2018) Amila Suraweera et al.   Frontiers in Oncology

Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance

(2018) Farzana Ahmed et al.   Frontiers in Oncology

A novel porcupine inhibitor blocks WNT pathways and attenuates cardiac hypertrophy

(2018) Jiahui Jiang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity

(2018) Christopher Dravis et al.   CANCER CELL

A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics

(2018) Léonie Ferrer et al.   Journal of Thoracic Oncology

Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI

(2018) Chien-Hui Weng et al.   ONCOGENE

Cellular Plasticity in Intestinal Homeostasis and Disease

(2018) Felipe de Sousa e Melo et al.   Cell Stem Cell

Bromodomain Drug Discovery – the Past, the Present, and the Future

(2018) Mehrosh Pervaiz et al.   CHEMICAL RECORD

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes

(2018) Nicolas Marcoux et al.   JOURNAL OF CLINICAL ONCOLOGY

A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition

(2018) Brian Biehs et al.   NATURE

A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy

(2018) Adriana Sánchez-Danés et al.   NATURE

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN

(2018) Quinlan L. Sievers et al.   SCIENCE

Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer

(2018) Anna C. Ferrari et al.   CLINICAL CANCER RESEARCH

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

(2017) June-Koo Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)

(2017) Pei-Pei Kung et al.   JOURNAL OF MEDICINAL CHEMISTRY

Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?

(2017) Sai-Hong Ignatius Ou et al.   LUNG CANCER

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma

(2017) Antonio Ahn et al.   MOLECULAR CANCER THERAPEUTICS

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer

(2017) Jing Shan Lim et al.   NATURE

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

(2017) Matthew J. Hangauer et al.   NATURE

Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

(2017) Vasanthi S. Viswanathan et al.   NATURE

The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer

(2017) Angela M. Krebs et al.   NATURE CELL BIOLOGY

EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

(2017) Tsukasa Shibue et al.   Nature Reviews Clinical Oncology

Persistent bacterial infections and persister cells

(2017) Robert A. Fisher et al.   NATURE REVIEWS MICROBIOLOGY

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

(2017) Yapeng Su et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer

(2017) Ping Mu et al.   SCIENCE

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

(2017) Sheng Yu Ku et al.   SCIENCE

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas

(2017) Sachin Jain et al.   OncoTargets and Therapy

Microenvironment-derived factors driving metastatic plasticity in melanoma

(2017) Isabella S. Kim et al.   Nature Communications

Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation

(2017) Chunying Song et al.   Cancer Discovery

Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex

(2017) Jon S. Zawistowski et al.   Cancer Discovery

A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors

(2017) Xuesong Zhao et al.   Cancer Discovery

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression

(2017) Maria Rusan et al.   Cancer Discovery

Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer

(2017) Min Zou et al.   Cancer Discovery

Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance

(2017) Mannan Nouri et al.   Oncotarget

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

(2017) Simon J. Hogg et al.   Cell Reports

Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance

(2017) Heinz Hammerlindl et al.   Journal of Cell Communication and Signaling

Transformation ofALKrearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib

(2016) N. Takegawa et al.   ANNALS OF ONCOLOGY

N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer

(2016) Etienne Dardenne et al.   CANCER CELL

SOX2 Is the Determining Oncogenic Switch in Promoting Lung Squamous Cell Carcinoma from Different Cells of Origin

(2016) Giustina Ferone et al.   CANCER CELL

Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy

(2016) Michael P. Smith et al.   CANCER CELL

EMT: 2016

(2016) M. Angela Nieto et al.   CELL

Replacement of Lost Lgr5-Positive Stem Cells through Plasticity of Their Enterocyte-Lineage Daughters

(2016) Paul W. Tetteh et al.   Cell Stem Cell

Cellular plasticity: 1712 to the present day

(2016) Purushothama Rao Tata et al.   CURRENT OPINION IN CELL BIOLOGY

Plasticity in the Adult: How Should the Waddington Diagram Be Applied to Regenerating Tissues?

(2016) Jayaraj Rajagopal et al.   DEVELOPMENTAL CELL

Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in Bone

(2016) Sambad Sharma et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas

(2016) Rishi G. Vaswani et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Jean Y Tang et al.   LANCET ONCOLOGY

Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma

(2016) Charline Caumont et al.   LUNG CANCER

Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor Growth

(2016) H. Jackson et al.   MOLECULAR CANCER RESEARCH

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma

(2016) Y. Qin et al.   MOLECULAR CANCER THERAPEUTICS

sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance

(2016) Amanpreet Kaur et al.   NATURE

Structural analysis of human KDM5B guides histone demethylase inhibitor development

(2016) Catrine Johansson et al.   Nature Chemical Biology

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer

(2016) Himisha Beltran et al.   NATURE MEDICINE

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

(2016) Aaron N Hata et al.   NATURE MEDICINE

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

(2016) I. Tirosh et al.   SCIENCE

Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability

(2016) D. R. Pattabiraman et al.   SCIENCE

Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?

(2016) Lidia Robert et al.   SEMINARS IN IMMUNOLOGY

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer

(2016) Jennifer L. Bishop et al.   Cancer Discovery

Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance

(2016) Molly Gale et al.   Oncotarget

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK Signaling

(2015) Eishu Hirata et al.   CANCER CELL

Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma

(2015) Scott X. Atwood et al.   CANCER CELL

Genomic Analysis of Smoothened Inhibitor Resistance in Basal Cell Carcinoma

(2015) Hayley J. Sharpe et al.   CANCER CELL

Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

(2015) Ji-Youn Han et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma

(2015) Naoki Oshimori et al.   CELL

A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma

(2015) Howard Sofen et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

(2015) Matthew G Oser et al.   LANCET ONCOLOGY

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

(2015) Chee-Seng Tan et al.   LANCET ONCOLOGY

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial

(2015) Nicole Basset-Seguin et al.   LANCET ONCOLOGY

Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer

(2015) Xiaofeng Zheng et al.   NATURE

Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance

(2015) Kari R. Fischer et al.   NATURE

Erratum: A stress-induced early innate response causes multidrug tolerance in melanoma

(2015) D Ravindran Menon et al.   ONCOGENE

Persisters unmasked

(2015) D. W. Holden   SCIENCE

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

(2015) Matthew J. Niederst et al.   Nature Communications

The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer

(2015) Shusuke Akamatsu et al.   Cell Reports

Polycomb-mediated silencing in neuroendocrine prostate cancer

(2015) Pier-Luc Clermont et al.   Clinical Epigenetics

EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway

(2015) Fumihiko Murai et al.   Cell Discovery

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

(2014) C. Wilson et al.   CANCER RESEARCH

A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral  -Secretase Inhibitor PF-03084014

(2014) W. A. Messersmith et al.   CLINICAL CANCER RESEARCH

Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis—A Systematic Review and Pooled Analysis

(2014) Hai Tao Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

(2014) Noemi Reguart et al.   LUNG CANCER

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

(2014) S. K. Knutson et al.   MOLECULAR CANCER THERAPEUTICS

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

(2014) Chong Sun et al.   NATURE

Kruidenier et al. reply

(2014) Laurens Kruidenier et al.   NATURE

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor

(2014) Nicholas Kwiatkowski et al.   NATURE

Inhibition of demethylases by GSK-J1/J4

(2014) Bo Heinemann et al.   NATURE

Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice

(2014) Jose Pedro Friedmann Angeli et al.   NATURE CELL BIOLOGY

An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia

(2014) Birgit Knoechel et al.   NATURE GENETICS

Can we safely target the WNT pathway?

(2014) Michael Kahn   NATURE REVIEWS DRUG DISCOVERY

Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma

(2014) A Roesch   ONCOGENE

Autophagy Pathway Is Required for IL-6 Induced Neuroendocrine Differentiation and Chemoresistance of Prostate Cancer LNCaP Cells

(2014) Pei-Ching Chang et al.   PLoS One

Multiple cells-of-origin of mutant K-Ras–induced mouse lung adenocarcinoma

(2014) Kate D. Sutherland et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Plasticity of epithelial stem cells in tissue regeneration

(2014) C. Blanpain et al.   SCIENCE

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

(2014) Judith Müller et al.   Nature Communications

The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF 

(2014) M. P. Smith et al.   Cancer Discovery

A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors

(2014) D. J. Konieczkowski et al.   Cancer Discovery

Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer

(2014) Masis Isikbay et al.   Hormones & Cancer

Directed Phenotype Switching as an Effective Antimelanoma Strategy

(2013) Magalí Sáez-Ayala et al.   CANCER CELL

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments

(2013) K. Masui et al.   CARCINOGENESIS

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

(2013) Vivek K. Arora et al.   CELL

The Sox Family of Transcription Factors: Versatile Regulators of Stem and Progenitor Cell Fate

(2013) Abby Sarkar et al.   Cell Stem Cell

Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis

(2013) Y. Touil et al.   CLINICAL CANCER RESEARCH

Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy

(2013) Prabhakar Rajan et al.   EUROPEAN UROLOGY

Small-Cell Carcinoma in the Setting of Pulmonary Adenocarcinoma: New Insights in the Era of Molecular Pathology

(2013) Emma Norkowski et al.   Journal of Thoracic Oncology

Rethinking the war on cancer

(2013) Douglas Hanahan   LANCET

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

(2013) Cory M. Johannessen et al.   NATURE

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

First Axl inhibitor enters clinical trials

(2013) Cormac Sheridan   NATURE BIOTECHNOLOGY

Microenvironmental regulation of tumor progression and metastasis

(2013) Daniela F Quail et al.   NATURE MEDICINE

A problem of persistence: still more questions than answers?

(2013) Nathalie Q. Balaban et al.   NATURE REVIEWS MICROBIOLOGY

REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer

(2013) C. Svensson et al.   NUCLEIC ACIDS RESEARCH

Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma

(2013) S. Mainardi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BCL2A1is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition

(2013) Rizwan Haq et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

(2013) J. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

(2013) M. J. Niederst et al.   Science Signaling

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic Melanoma

(2013) E. M. Van Allen et al.   Cancer Discovery

Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1

(2012) Oscar H. Ocaña et al.   CANCER CELL

Spatiotemporal Regulation of Epithelial-Mesenchymal Transition Is Essential for Squamous Cell Carcinoma Metastasis

(2012) Jeff H. Tsai et al.   CANCER CELL

Adult Murine Prostate Basal and Luminal Cells Are Self-Sustained Lineages that Can Both Serve as Targets for Prostate Cancer Initiation

(2012) Nahyun Choi et al.   CANCER CELL

Pharmacological Inhibition of the Wnt Acyltransferase PORCN Prevents Growth of WNT-Driven Mammary Cancer

(2012) K. D. Proffitt et al.   CANCER RESEARCH

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

(2012) U. Banerji et al.   CLINICAL CANCER RESEARCH

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain

(2012) Si-Eun Yoo et al.   FREE RADICAL BIOLOGY AND MEDICINE

A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer

(2012) Gary Hudes et al.   INVESTIGATIONAL NEW DRUGS

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

(2012) Ian Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer

(2012) Anna V Lapuk et al.   JOURNAL OF PATHOLOGY

Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma

(2012) Michael P. Smith et al.   JNCI-Journal of the National Cancer Institute

A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response

(2012) Laurens Kruidenier et al.   NATURE

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation

(2012) Khalil Kass Youssef et al.   NATURE CELL BIOLOGY

Dll1+ secretory progenitor cells revert to stem cells upon crypt damage

(2012) Johan H. van Es et al.   NATURE CELL BIOLOGY

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B

(2012) Yu Sun et al.   NATURE MEDICINE

Targeting the TGFβ signalling pathway in disease

(2012) Rosemary J. Akhurst et al.   NATURE REVIEWS DRUG DISCOVERY

TGFβ signalling in context

(2012) Joan Massagué   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

(2012) Aleksandar Sekulic et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cells of origin for cancer: an updated view from prostate cancer

(2012) L Xin   ONCOGENE

Snail1 Mediates Hypoxia-Induced Melanoma Progression

(2011) Shujing Liu et al.   AMERICAN JOURNAL OF PATHOLOGY

Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung

(2011) Kate D. Sutherland et al.   CANCER CELL

Characterization of the cell of origin for small cell lung cancer

(2011) Kwon-Sik Park et al.   CELL CYCLE

Distinct stem cells contribute to mammary gland development and maintenance

(2011) Alexandra Van Keymeulen et al.   NATURE

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Transcription factors that mediate epithelial–mesenchymal transition lead to multidrug resistance by upregulating ABC transporters

(2011) M Saxena et al.   Cell Death & Disease

Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

(2011) H. Beltran et al.   Cancer Discovery

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer

(2010) T. B. Dorff et al.   CLINICAL CANCER RESEARCH

TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate☆

(2010) Charles C. Guo et al.   HUMAN PATHOLOGY

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

(2010) Jin-Haeng Chung et al.   LUNG CANCER

Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells

(2010) Pinar Uysal-Onganer et al.   Molecular Cancer

Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies

(2010) Yan Gong et al.   PLoS One

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epithelial-Mesenchymal Transition-Derived Cells Exhibit Multilineage Differentiation Potential Similar to Mesenchymal Stem Cells

(2010) Venkata Lokesh Battula et al.   STEM CELLS

GDC-0449—A potent inhibitor of the hedgehog pathway

(2009) Kirk D. Robarge et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer

(2009) K. E. Knudsen et al.   CLINICAL CANCER RESEARCH

Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

(2009) R. L. Yauch et al.   SCIENCE

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH

Resistance mechanisms to cancer chemotherapy

(2008) Kelly Marie Redmond   Frontiers in Bioscience-Landmark

Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line

(2008) Jin Kyung Rho et al.   LUNG CANCER

Prostate tumor progression is mediated by a paracrine TGF-β/Wnt3a signaling axis

(2008) X Li et al.   ONCOGENE

Mechanisms of Disease: cancer stem cells—targeting the evil twin

(2008) Andreas Trumpp et al.   Nature clinical practice. Oncology